Earnings summaries and quarterly performance for Progyny.
Executive leadership at Progyny.
Board of directors at Progyny.
Research analysts who have asked questions during Progyny earnings calls.
Jailendra Singh
Truist Securities
4 questions for PGNY
Also covers: ACCD, AGL, AMWL +16 more
Sarah James
Cantor Fitzgerald
4 questions for PGNY
Also covers: ACHC, AMED, CI +15 more
Allen Lutz
Bank of America
3 questions for PGNY
Also covers: ACCD, CAH, COR +14 more
AM
Anne McCormick
JPMorgan Chase & Co.
3 questions for PGNY
Also covers: DOCS, HCAT, HQY +4 more
David Larsen
BTIG
3 questions for PGNY
Also covers: ACCD, AGL, AMWL +19 more
Michael Cherny
Leerink Partners
3 questions for PGNY
Also covers: ACCD, ALGN, CAH +18 more
Scott Schoenhaus
KeyBanc Capital Markets
3 questions for PGNY
Also covers: ALIT, CERT, DOCS +8 more
Brian Tanquilut
Jefferies
1 question for PGNY
Also covers: ACHC, ADUS, AHCO +29 more
CD
Constantine Davides
Citizens JMP
1 question for PGNY
Also covers: ADUS, AMN, CCRN +9 more
Daniel Clark
Leerink Partners
1 question for PGNY
Also covers: CERT, ELAN, IDXX +3 more
GS
Glen Santangelo
Jefferies
1 question for PGNY
Also covers: ALGN, ANIP, BHC +12 more
JS
Jenny Shen
TD Cowen
1 question for PGNY
Also covers: AGL, CCSI, CYRX +8 more
JP
John Penny
Canaccord Genuity
1 question for PGNY
Richard Close
Canaccord Genuity Group
1 question for PGNY
Also covers: ACCD, AHCO, CLOV +15 more
SD
Stephanie Davis
Barclays
1 question for PGNY
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for PGNY.
Progyny Highlights Strong Growth and Strategic Expansion
PGNY
Product Launch
M&A
Share Buyback
- Progyny has demonstrated significant financial performance, reporting a 33% revenue CAGR and 51% Adjusted EBITDA CAGR from 2019 through 2025, with $665 million in cumulative operating cash flow from 2019 through September 30, 2025.
- The company showcases effective cost management, with its medical cost trend increasing by 5% from 2022-2025, significantly lower than the 27% U.S. medical cost trend, and achieving ~30% savings through superior clinical outcomes.
- Progyny is expanding its client base, projecting over 600 clients in 2026, and has launched Progyny Select, a pooled risk model for smaller employers, though it is not expected to contribute financially until 2027.
- Strategic growth initiatives include global expansion, marked by the acquisition of Apryl in early 2024, and plans to introduce pregnancy, post-partum, and menopause services in 2026.
- The company maintains strong cash flow conversion, at 80% for 2024 and 9 months of 2025, and prioritizes capital allocation towards share repurchases, business expansion, and disciplined M&A.
Jan 13, 2026, 3:30 PM
Progyny Discusses 2025 Performance, New Products, and 2026 Outlook at J.P. Morgan Healthcare Conference
PGNY
Product Launch
New Projects/Investments
Guidance Update
- Progyny reported a strong 2025 selling season, adding 900,000 lives and achieving near 100% client retention across over 600 clients. The company also highlighted successful diversification, reducing its largest industry concentration from 18% in 2024 to a projected 15% in 2026, and its largest client is expected to represent a mid-single-digit percentage of revenue in 2026.
- The company launched Progyny Select, a new fully insured, pooled risk solution targeting employers with 100+ employees, which expands its addressable market by 50 million additional covered lives. Financial contribution from Select is anticipated starting in 2027.
- Progyny has expanded its service offerings to include pregnancy, postpartum, parenting, leave and benefit navigation, and menopause, with a third of its core book participating in these new services in 2026. The company also expanded its global offering, adding pregnancy, postpartum, and menopause care resources in 2026 following the 2024 acquisition of Apryl.
- Progyny expects fourth-quarter 2025 results to be slightly above its guidance range due to strengthening demand and utilization. The company's capital deployment priorities include expanding offerings, investing in go-to-market, selective M&A, and ongoing share repurchase programs.
Jan 13, 2026, 3:30 PM
Progyny Outlines 2026 Strategy, New Offerings, and Market Diversification
PGNY
Product Launch
New Projects/Investments
Guidance Update
- Progyny introduced Progyny Select, a new fully insured solution for small employers (100+ employees), which expands its addressable market by 50 million additional covered lives and is expected to contribute financially starting in 2027.
- The company reported a successful 2025 selling season, adding 900,000 lives and achieving near 100% client retention, with 30% of clients expanding their benefits.
- Progyny has significantly diversified its client base, reducing its largest industry concentration from 18% in 2024 to 15% in 2026, and projects its largest client to represent only a mid-single-digit percentage of revenue in 2026.
- The company expects fourth-quarter results to be slightly above its guidance range due to strengthening demand and utilization.
- Progyny continues to expand its services, including new offerings for pregnancy, postpartum, parenting, Leave and Benefit Navigation, and menopause, and is expanding its global offering following the 2024 acquisition of Apryl.
Jan 13, 2026, 3:30 PM
Progyny Discusses 2025 Selling Season Success, New Product Launches, and 2026 Outlook
PGNY
Product Launch
New Projects/Investments
Share Buyback
- Progyny reported a successful 2025 selling season, adding an additional 900,000 lives and achieving close to 100% client retention.
- The company has significantly diversified its client base, with the largest industry representing 15% of lives in 2024 (down from 18%) and the largest client projected to be a mid-single-digit client in 2026.
- Progyny launched "Progyny Select," a new solution for small employers (100+ employees) that expands its addressable market by 50 million additional covered lives, with financial contribution expected to begin in 2027.
- The company expects fourth-quarter results to be slightly above its guidance range due to continued and strengthening demand.
- Capital deployment priorities include expanding offerings, investing in go-to-market resources, selective M&A, and returning value to shareholders through share repurchase programs, including a $200 million program announced in November.
Jan 13, 2026, 3:30 PM
Progyny Updates Financial Expectations for Q4 and Full Year 2025
PGNY
Guidance Update
Earnings
Revenue Acceleration/Inflection
- Progyny, Inc. announced it will discuss updated financial expectations for the fourth quarter and full year ending December 31, 2025, at the JP Morgan Healthcare Conference on January 13, 2026.
- The company anticipates its fourth quarter 2025 results for revenue, net income, and Adjusted EBITDA to be slightly above the ranges previously provided in November.
- This positive revision is primarily due to favorable member engagement during the fourth quarter.
Jan 12, 2026, 1:12 PM
Progyny Discusses Growth Strategy, Market Expansion, and Capital Deployment at Jefferies Conference
PGNY
New Projects/Investments
Share Buyback
M&A
- Progyny, a leading provider of fertility benefits and women's health solutions, expects to cover 7.6 million lives and serve 600 customers by 2026, representing a high single-digit penetration of its 106 million life addressable market.
- The company added 900,000 lives in the last selling season and aims to add at least 1 million lives annually.
- Progyny is expanding its total addressable market (TAM) by approximately 50% with its entry into the small and middle-market employer sector, which will add an additional 50 million lives starting in 2026.
- New women's health products, including menopause, pregnancy, postpartum, and leave benefit navigation, are expected to contribute 8% to 10% of revenue by 2028, with 2.7 million lives having access to these expanded offerings in 2026.
- The company's capital deployment strategy prioritizes platform expansion, go-to-market investments for new products, M&A, and share repurchases, supported by $345 million in cash and cash equivalents and a $200 million line of credit.
Nov 18, 2025, 3:00 PM
Progyny Discusses Market Expansion and New Product Growth at 2025 Jefferies Conference
PGNY
New Projects/Investments
Revenue Acceleration/Inflection
Share Buyback
- Progyny, a leading provider of fertility benefits, expects to cover approximately 7.6 million lives across 600 customers by 2026, having added 900,000 lives in the most recent selling season. This represents high single-digit penetration of its 106 million addressable market.
- The company is expanding its total addressable market by entering the small and middle-market employer sector, which will add an estimated 50 million lives and is set to launch in 2026.
- New women's health products, including menopause, pregnancy, postpartum, and leave benefit navigation, will be accessible to 2.7 million lives (approximately one-third of its base) by 2026 and are projected to contribute 8% to 10% of revenue by 2028.
- Progyny reported a historical client retention rate of near 100% and holds $345 million in cash and cash equivalents, with capital deployment priorities including platform expansion, M&A, and share repurchases.
Nov 18, 2025, 3:00 PM
Progyny Outlines Growth Strategy, Market Expansion, and Capital Deployment
PGNY
New Projects/Investments
Guidance Update
Share Buyback
- Progyny, a leading provider of fertility benefits, anticipates reaching 7.6 million lives and 600 customers by 2026, with a current addressable market of 106 million lives. The company added 900,000 lives in the recent selling season, aiming for at least 1 million annual additions.
- The company is expanding its total addressable market by entering the small and middle-market employer sector, which is expected to add an additional 50 million lives and be in market by 2026.
- New product offerings in women's health, including menopause and pregnancy solutions, will be accessible to 2.7 million lives by 2026 and are projected to contribute 8% to 10% of revenue by 2028.
- Progyny maintains a near 100% client renewal rate and has a clear capital deployment strategy focusing on platform expansion, new product go-to-market, M&A, and share repurchases, backed by $345 million in cash and a $200 million credit line.
Nov 18, 2025, 3:00 PM
PGNY Reports Strong Q3 2025 Financial Results and Updates Full-Year Guidance
PGNY
Earnings
Guidance Update
Share Buyback
- PGNY reported Q3 2025 revenue of $313.3 million, representing 9.3% growth compared to Q3 2024, and year-to-date revenue of $970.3 million, an increase of 12% from the prior year.
- Adjusted EBITDA increased 18% to $55.0 million in Q3 2025, yielding a 17.5% margin, and year-to-date Adjusted EBITDA grew 13% to $170.7 million. Gross profit also saw a 23% increase in Q3 2025 and a 20% increase year-to-date.
- The company generated $50.7 million in operating cash flow for Q3 2025 and $156.0 million year-to-date 2025.
- A new authorization for a share repurchase program of up to $200 million was announced.
- For the full year 2025, PGNY projects revenue between $1.263 billion and $1.278 billion and Adjusted EBITDA between $216.0 million and $220.0 million.
Nov 6, 2025, 9:45 PM
Progyny Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Announces Share Repurchase Program
PGNY
Earnings
Guidance Update
Share Buyback
- Progyny reported a strong third quarter of 2025, with revenue and profitability exceeding the high end of its guidance ranges. The company subsequently raised its full-year 2025 guidance, projecting revenue between $1.263 billion and $1.278 billion and adjusted EBITDA between $216 million and $220 million.
- In Q3 2025, revenue grew 9% on an as-reported basis, or 23% when excluding the impact of a large former client. The company generated over $50 million in operating cash flow during the quarter, contributing to a record $156 million over the first nine months of the year.
- The latest selling season resulted in over 80 new logos and approximately 900,000 new covered lives for 2026, maintaining a near 100% renewal rate of existing clients. Additionally, nearly 30% of clients expanded their benefits for 2026.
- Progyny is expanding its offerings with a new supplemental plan for fertility and family building aimed at small and mid-sized companies, and has launched the Progyny Global offering for multinational employers.
- The board has authorized a new share repurchase program for up to $200 million, leveraging the company's strong balance sheet which includes $345 million in cash, cash equivalents, and marketable securities as of September 30th.
Nov 6, 2025, 9:45 PM
Quarterly earnings call transcripts for Progyny.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more